Document Classification

Section Type: RESULTS

Text: The mean decline in serum ALT activity at the end of treatment did not differ significantly (P =. 75) across the 3 treatment groups (mean decline, -4. 3 [95 % CI, -17. 3 to 8. 7] U/L for placebo, -14. 4 [95 % CI, -41. 6 to 12. 7] U/L for 420-mg silymarin, -11. 3 [95 % CI, -27. 9 to 5. 4] U/L for 700-mg silymarin) ; there likewise were no significant differences in HCV RNA levels (mean change, 0. 07 [95 % CI, -0. 05 to 0. 18] log10 IU/mL for placebo, -0. 03 [95 % CI, -0. 18 to 0. 12] log10 IU/mL for 420-mg silymarin, 0. 04 [95 % CI, -0. 08 to 0. 16] log10 IU/mL for 700-mg silymarin ; P =. 54) or quality-of-life measures.